research MP89-08 POST-FINASTERIDE SYNDROME: REAL OR IMAGINED?
Finasteride 1mg linked to diverse symptoms; other treatments improve erectile function in rats.
Search
for
Sort by
Research
330-360 / 1000+ results research Phytochemicals With Anti 5-alpha-reductase Activity: A Prospective For Prostate Cancer Treatment
Plant-based compounds might be effective, low-side-effect treatments for prostate cancer by blocking a specific enzyme.
research 5α-Reductase inhibitors in androgenetic alopecia
Finasteride and dutasteride effectively treat hair loss in men and women, but may cause side effects like low libido and depression.
research Treatment of Recurrent Priapism in Sickle Cell Anemia With Finasteride: A New Approach
research Treatment of Recurrent Priapism in Sickle Cell Anemia With Finasteride: A New Approach
research Comparison of clinical trials with finasteride and dutasteride.
Dutasteride reduces DHT more than finasteride, but both drugs improve BPH symptoms similarly.
research Sexual side effects of 5-α-reductase inhibitors finasteride and dutasteride: A comprehensive review
Finasteride and dutasteride can cause sexual problems like impotence and low libido.
research Clinical application of 5α-reductase inhibitors
5α-reductase inhibitors, like finasteride and dutasteride, effectively treat BPH, male baldness, and hirsutism, with potential for acne and prostate cancer prevention.
research A randomized placebo-controlled multicentre study to evaluate the safety and efficacy of finasteride for male chronic pelvic pain syndrome (category IIIA chronic nonbacterial prostatitis).
Finasteride may help some male chronic pelvic pain patients, but more research needed.
research 332 FINASTERIDE FOR RECURRENT PRIAPISM IN CHILDREN AND ADOLESCENTS WITH SICKLE CELL DISEASE (SCD). REPORT OF 5 CASES
Finasteride effectively reduced priapism episodes in children with sickle cell disease without side effects.
research A proposed etiopathology of persistent dysfunctions emerging from use and discontinuation of 5-alpha reductase inhibitors: sequelae of drug-mediated microvasculopathy
The document suggests that drugs for prostate issues might cause lasting sexual, mental, and physical health problems due to blood vessel damage in the penis.
research FINASTERIDE AND PSA
research Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia.
Dutasteride may lower the chance of finding prostate cancer in men with enlarged prostates.
research Finasteride reduces serum PSA to a similar extent at 1 mg and 5 mg daily doses
Finasteride lowers PSA levels about the same whether taken at 1 mg or 5 mg daily.
research 5‐Alpha reductase inhibitor related litigation: A legal database review
Most legal cases about 5α-reductase inhibitors, drugs for hair loss and prostate issues, complain about side effects and delayed cancer diagnosis, with most lawsuits settled out of court.
research Development of a Doxazosin and Finasteride Transdermal System for Combination Therapy of Benign Prostatic Hyperplasia
Researchers created a skin patch that delivers two drugs for treating enlarged prostate, which may improve patient use and dosage control.
research Effects of prasugrel versus clopidogrel on coronary microvascular function in patients undergoing elective percutaneous coronary intervention: A randomized double-blind study
Prasugrel is better than clopidogrel at preventing heart damage and improving blood flow in small heart vessels during heart artery procedures.
research Is finasteride intake associated with penile curvature/peyronie’s disease? Assessment of both the food and drug administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases
research New 5?-reductase inhibitors: In vitro and in vivo effects
Four new compounds were more effective than finasteride in treating prostate issues and hair loss, with one being 100 times more active and safe for use.
research 5-Alpha-Reductase Inhibitors Reduce Remission Time of COVID-19: Results From a Randomized Double Blind Placebo Controlled Interventional Trial in 130 SARS-CoV-2 Positive Men
5-Alpha-Reductase inhibitors shorten COVID-19 recovery time in men.
research Drug–Drug Coamorphous System of Tadalafil and Finasteride for Enhanced Pharmaceutical Performance
Combining tadalafil and finasteride improves their solubility and effectiveness.
research Medications Mostly Associated With Ejaculatory Disorders: Assessment of the Eudra-Vigilance and Food and Drug Administration Pharmacovigilance Databases Entries
Certain medications, especially Paroxetine, Tamsulosin, and Finasteride, are linked to ejaculatory disorders.
research Efeitos da finasterida sobre culturas de células epiteliais prostáticas normais e tumorais em diferentes sistemas in vitro
Finasteride may reduce prostate tumor cell invasion and spread.
research Investigation of the Plausibility of 5-Alpha-Reductase Inhibitor Syndrome
The document concludes that sexual and psychiatric side effects from 5-alpha-reductase inhibitors are reported, but more high-quality research is needed to understand how often they occur.
research Medikamentöse Therapie des benignen Prostatasyndroms (BPS)
Combination drug therapies are more effective for high-risk BPS patients but have more side effects and costs.
research Evaluation of intralesional injection of platelet derived growth factors PDGF ma in patients with Peyronie's disease
LGF injections may improve early Peyronie's disease by reducing penile curvature and plaque size.
research La combinación de finasteride y doxazosina fue más efectiva que la monoterapia en la hiperplasia prostática benigna
Using finasteride and doxazosina together works better for treating benign prostatic hyperplasia than using just one.
research Dutasteride/finasteride
Finasteride and dutasteride may cause macular abnormalities.
research Selective non-steroidal inhibitors of 5α-reductase type 1
Selective non-steroidal inhibitors of 5α-reductase type 1 can help treat DHT-related disorders.
research PD16-01 NEW INSIGHT OF PSA REDUCTION DURING FINASTERIDE THERAPY
Finasteride reduces PSA levels by around 40-50% in BPH patients.